CaMKII, that binds with ligustilide, as a potential drug target of Suxiao jiuxin pill, a traditional Chinese medicine to dilate thoracic aorta

Preparation of a cattle bone collagen peptide–calcium chelate by the ultrasound method and its structural characterization, stability analysis, and bioactivity on MC3T3-E1 cells

“…Based on our previous study of the sequence of cattle bone collagen peptides, 34 the amino acid repeating sequence [Gly–X–Y] n (X and Y are mostly proline and hydroxyproline) of collagen, and Glu and Asp are important sites for calcium ions chelating with peptides, 49 the collagen peptides of SGE, TGE, AGE, ASGE, GEAGAQ, GPAGE, GPAGER, and GDTGAK were chosen to carry out molecular docking with CaMKII. Lu et al 50 indicated that ligustilide (E-Lig) could bind with CaMKII as a potential drug target of suxiao jiuxin pill. Thus, E-Lig was chosen as a positive control to evaluate the interaction between collagen peptides and CaMKII.…”

Suxiao Jiuxin Pill attenuates acute myocardial ischemia via regulation of coronary artery tone

“…Moreover, uprosertib, an Akt inhibitor, inhibited both Akt phosphorylation and endothelium-dependent relaxation, demonstrating that senkyunolide A induced vascular tone changes in rat-isolated coronary arteries via the endothelium Akt-eNOS-NO pathway. Senkyunolide A and ligustilide from Suxiao Jiuxin Pill showed Ca 2+ -inhibitory activity by activating CaMKII in VSMCs and causing thoracic aortic relaxation ( Lu, Y. et al, 2022 ). These results suggest that senkyunolide A causes vasorelaxation by increasing CaMKII activity in VSMCs and activating the Akt/eNOS/NO pathway in endothelial cells.…”

CaMKII: Therapeutic target in vascular diseases warranted for Clinical and Translational Discovery?

“…Recently, Lu et al 12 reported a brand new druggable site on CaMKII that can be targeted by a pre-existing traditional Chinese medicine with demonstrated benefits in alleviating cardiovascular symptoms among hospitalised atherosclerotic patients. Through iTRAQ1-based differential proteomic analysis and subsequent verification, CaMKII was identified as a potential target.…”

“…Recently, Lu et al 12 . reported a brand new druggable site on CaMKII that can be targeted by a pre‐existing traditional Chinese medicine with demonstrated benefits in alleviating cardiovascular symptoms among hospitalised atherosclerotic patients.…”